The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
1. Hunger, S.P., et al., Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012.30 (14): p. 1663-1669.
2. Ranta, S., et al., Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. 2015.
3. Silverman, L.B., et al., Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, 2001. 97 (5): p. 1211-8.
4. Ghanem, K.M., et al., Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatric Blood & Cancer, 2017. 64 (12): p. e26694.
5. Pui, C.H., et al., Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med, 2009.360 (26): p. 2730-41.
6. Muwakkit, S., et al., Implementation of an intensive risk-stratified treatment protocol for children and adolescents with acute lymphoblastic leukemia in Lebanon. American Journal of Hematology, 2012. 87 (7): p. 678-683.
7. Caruso, V., et al., Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood, 2006. 108 (7): p. 2216-22.
8. Musgrave, K.M., et al., Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom. Br J Haematol, 2017. 179 (4): p. 667-669.
9. Tamim, H., R.R. Finan, and W.Y. Almawi, Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost, 2002.88 (4): p. 691-2.
10. Nowak-Göttl, U., et al., Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood, 2003. 101 (7): p. 2529-2533.
11. Kujovich, J.L., Factor V Leiden thrombophilia. Genet Med, 2011. 13 (1): p. 1-16.
12. Nowak-Göttl, U., et al., Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors. Blood, 1999. 93 (5): p. 1595-1599.
13. Raffini, L. and C. Thornburg, Testing children for inherited thrombophilia: more questions than answers. British Journal of Haematology, 2009. 147 (3): p. 277-288.
14. Tozuka, M., et al., Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma. Ann Clin Lab Sci, 1997. 27 (5): p. 351-7.
15. Ridola, V., et al., Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer, 2008. 50 (2): p. 378-80.
16. Finch, E.R., et al., Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.Pediatric Blood & Cancer, 2020. 67 (1): p. e28040.
17. Bendjelid, K., Body habitus should not considerably affect the interpretation of hemodynamic measurements: huge news? Crit Care Med, 2006. 34 (4): p. 1289-90.
18. Blatt, J., et al., Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. Leukemia, 1993.7 (11): p. 1734-7.
19. Franchini, M. and M. Makris, Non-O blood group: an important genetic risk factor for venous thromboembolism. Blood Transfus, 2013.11 (2): p. 164-5.